HERC5 antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q9UII4 |
Other Accession | NM_016323, NP_057407 |
Reactivity | Human, Bovine, Dog |
Predicted | Human, Bovine, Dog |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 117kDa |
Gene ID | 51191 |
---|---|
Alias Symbol | CEB1, CEBP1 |
Other Names | E3 ISG15--protein ligase HERC5, 6.3.2.-, Cyclin-E-binding protein 1, HECT domain and RCC1-like domain-containing protein 5, HERC5, CEB1, CEBP1 |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-HERC5 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | HERC5 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | HERC5 |
---|---|
Synonyms | CEB1, CEBP1 |
Function | Major E3 ligase for ISG15 conjugation (PubMed:26355087, PubMed:27564865, PubMed:27534820, PubMed:34572049, PubMed:37279284). Acts as a positive regulator of innate antiviral response in cells induced by interferon. Functions as part of the ISGylation machinery that recognizes target proteins in a broad and relatively non-specific manner. Catalyzes ISGylation of IRF3 which results in sustained activation, it attenuates IRF3-PIN1 interaction, which antagonizes IRF3 ubiquitination and degradation, and boosts the antiviral response. Mediates ISGylation of the phosphatase PTEN leading to its degradation, thus alleviating its suppression of the PI3K-AKT signaling pathway and promoting the production of cytokines that facilitate bacterial clearance (PubMed:37279284). Interferes with the function of key viral structural proteins such as ebolavirus structural protein VP40 or HIV-1 protein GAG (PubMed:22093708, PubMed:34572049). Catalyzes ISGylation of influenza A viral NS1 which attenuates virulence; ISGylated NS1 fails to form homodimers and thus to interact with its RNA targets. Catalyzes ISGylation of papillomavirus type 16 L1 protein which results in dominant-negative effect on virus infectivity. Physically associated with polyribosomes, broadly modifies newly synthesized proteins in a cotranslational manner. In an interferon-stimulated cell, newly translated viral proteins are primary targets of ISG15. Promotes parkin/PRKN ubiquitin E3 ligase activity by suppressing the intramolecular interaction that maintains its autoinhibited conformation (PubMed:27534820). |
Cellular Location | Cytoplasm, perinuclear region. Cytoplasm Note=Associated with the polyribosomes, probably via the 60S subunit |
Tissue Location | Expressed in testis and to a lesser degree in brain, ovary and placenta. Found in most tissues at low levels |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Salon,C.,(2007)Oncogene26(48),6927-6936ReconstitutionandStorage:Forshorttermuse,storeat2-8Cupto1week.Forlongtermstorage,storeat-20Cinsmallaliquotstopreventfreeze-thawcycles.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.